-
公开(公告)号:US20060166983A1
公开(公告)日:2006-07-27
申请号:US10541555
申请日:2003-12-31
申请人: Scott Conner , James Knobelsdorf , Nathan Mantlo , Daniel Mayhugh , Xiaodong Wang , Guoxin Zhu , Jeffrey Schkeryantz , Pierre-Yves Michellys
发明人: Scott Conner , James Knobelsdorf , Nathan Mantlo , Daniel Mayhugh , Xiaodong Wang , Guoxin Zhu , Jeffrey Schkeryantz , Pierre-Yves Michellys
IPC分类号: A61K31/5377 , A61K31/454 , A61K31/4439 , A61K31/405 , C07D413/02 , C07D405/02 , C07D403/02
CPC分类号: C07D209/08 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
摘要: The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in (I) are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.
摘要翻译: 本发明涉及一种通过使用结构式(I)的化合物调节过氧化物酶体增殖物激活受体的治疗方法。 (I)中的变量在本文中定义。 还包括化合物,制备化合物的方法和药物组合物。 据信本发明的化合物在治疗和预防X综合征,II型糖尿病,高血糖症,高脂血症,肥胖,凝血病,高血压,动脉粥样硬化以及与X综合征和心血管疾病相关的其它疾病方面是有效的。
-
公开(公告)号:US20070173526A1
公开(公告)日:2007-07-26
申请号:US10598473
申请日:2005-03-17
申请人: Michael Bell , Guoqing Cao , Ana Escribano , Maria Fernandez , Peter Lander , Nathan Mantlo , Eva Martin de la Nava , Ana Mateo Herranz , Daniel Mayhugh , Xiaodong Wang
发明人: Michael Bell , Guoqing Cao , Ana Escribano , Maria Fernandez , Peter Lander , Nathan Mantlo , Eva Martin de la Nava , Ana Mateo Herranz , Daniel Mayhugh , Xiaodong Wang
IPC分类号: A61K31/4745 , A61K31/4743 , C07D498/02 , C07D471/02
CPC分类号: C07D495/04 , C07D471/04 , C07D487/04
摘要: The present invention discloses compounds of formula (I) wherein A, n, q, K, W, X, Y; Z, R1, R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and its sequelae.
摘要翻译: 本发明公开了式(I)的化合物,其中A,n,q,K,W,X,Y; Z,R 1,R 2,R 3,R 4,R 5,..., >和R 6'如本文所定义,并且其药物组合物和使用方法被公开用于治疗血脂异常及其后遗症。
-
公开(公告)号:US20060241157A1
公开(公告)日:2006-10-26
申请号:US10540341
申请日:2003-12-31
申请人: Scott Conner , Tianwei Ma , Nathan Mantlo , Daniel Mayhugh , Jeffrey Schkeryantz , Alan Warshawsky , Guoxin Zhu
发明人: Scott Conner , Tianwei Ma , Nathan Mantlo , Daniel Mayhugh , Jeffrey Schkeryantz , Alan Warshawsky , Guoxin Zhu
IPC分类号: A61K31/425 , A61K31/42 , A61K31/415 , C07D261/02 , C07D231/12
CPC分类号: C07D231/12 , C07D233/20 , C07D233/22 , C07D233/64 , C07D249/06 , C07D253/04 , C07D261/08
摘要: The present invention is directed to compounds represented by the following structural formula, Formula I: wherein: (a) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of O, C, S, NH and a single bond; (d) E is C(R3)(R4)A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamide, sulfonamide and acylsulfonamide; (e) Z1 and Z2 are each independently selected from the group consisting of N, O, and C with the proviso that at least one of Z1 and Z2 is N; (f) Z3 is selected from the group consisting of N, O, and C. (g) R8 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C4 alkylenyl and halo; (h) R9 is selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 alkylenyl, halo, aryl-C0-C4 alkyl, heteroaryl, C1-C6 allyl, and OR29.
摘要翻译: 本发明涉及由以下结构式(I)表示的化合物:其中:(a)X选自单键,O,S,S(O)2和N; (b)U是脂族连接体; (c)Y选自O,C,S,NH和单键; (d)E是C(R3)(R4)A或A,其中(i)A选自羧基,四唑,C 1 -C 6烷基腈,甲酰胺,磺酰胺和酰基磺酰胺; (e)Z1和Z2各自独立地选自N,O和C,条件是Z1和Z2中的至少一个是N; (f)Z 3选自N,O和C.(g)R 8选自氢,C 1 -C 6烷基,C 1 -C 4亚烷基和卤素; (h)R 9选自氢,C 1 -C 4烷基,C 1 -C 4亚烷基,卤素,芳基-C 0 -C 4烷基,杂芳基,C 1 -C 6烯丙基和OR 29。
-
公开(公告)号:US20070208003A1
公开(公告)日:2007-09-06
申请号:US10598686
申请日:2005-03-17
申请人: Michael Bell , Guoqing Cao , Ana Escribano , Maria Fernandez , Nathan Mantlo , Eva Martin de la Nava , Ana Mateo Herranz , Daniel Mayhugh , Xiadong Wang
发明人: Michael Bell , Guoqing Cao , Ana Escribano , Maria Fernandez , Nathan Mantlo , Eva Martin de la Nava , Ana Mateo Herranz , Daniel Mayhugh , Xiadong Wang
IPC分类号: A61K31/55 , C07D498/02 , C07D487/02
CPC分类号: C07D495/04 , C07D471/04 , C07D487/04
摘要: The present invention discloses compounds of formula I wherein A, n, m, j, q, y, W, X, Y, Z, R1, R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and its sequelae.
摘要翻译: 本发明公开了式I的化合物,其中A,n,m,j,q,y,w,X,Y,Z,R 1,R 2,R R 4,R 5,R 5和R 6如本文所定义,并且它们的药物组合物和方法 公开了用于治疗血脂异常及其后遗症的用途。
-
公开(公告)号:US20070043220A1
公开(公告)日:2007-02-22
申请号:US10537282
申请日:2003-12-31
申请人: Scott Conner , Nathan Mantlo , Daniel Mayhugh , Guoxin Zhu
发明人: Scott Conner , Nathan Mantlo , Daniel Mayhugh , Guoxin Zhu
IPC分类号: C07D231/12 , A61K31/4152
CPC分类号: C07D231/12 , C07D233/20 , C07D233/22 , C07D233/64 , C07D249/06 , C07D253/04 , C07D261/08
摘要: The present invention is directed to a compound, {2-Methyl-4-[3-methyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazol-4-ylmethylsulfanyl]-phenoxy}-acetic acid and pharmaceutical uses thereof.
摘要翻译: 本发明涉及化合物{2-甲基-4- [3-甲基-1-(4-三氟甲基 - 苯基)-1H-吡唑-4-基甲基硫烷基] - 苯氧基} - 乙酸及其药物用途。
-
公开(公告)号:US20060217374A1
公开(公告)日:2006-09-28
申请号:US10541502
申请日:2003-12-31
申请人: Scott Conner , James Knobelsdorg , Nathan Mantlo , Daniel Mayhugh , Xiaodong Wang , Guoxin Zhu , Jeffrey Schkeryantz
发明人: Scott Conner , James Knobelsdorg , Nathan Mantlo , Daniel Mayhugh , Xiaodong Wang , Guoxin Zhu , Jeffrey Schkeryantz
IPC分类号: A61K31/5377 , A61K31/4245 , A61K31/4196 , A61K31/4178 , C07D403/02 , C07D409/02 , C07D413/02
CPC分类号: C07D263/57 , C07D209/10 , C07D235/18 , C07D277/60 , C07D277/66 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D513/04
摘要: The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in I are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type H diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.
摘要翻译: 本发明涉及一种通过使用结构式(I)的化合物调节过氧化物酶体增殖物激活受体的治疗方法。 I中的变量在此定义。 还包括化合物,制备化合物的方法和药物组合物。 认为本发明的化合物可有效治疗和预防X综合征,H型糖尿病,高血糖症,高脂血症,肥胖症,凝血病,高血压,动脉粥样硬化以及与X综合征和心血管疾病相关的其他疾病。
-
公开(公告)号:US20070254869A1
公开(公告)日:2007-11-01
申请号:US10574649
申请日:2004-10-07
申请人: Guoqing Cao , Ana Escribano , Maria Fernandez , Todd Fields , Douglas Gernert , Christopher Cioffi , Robert Herr , Nathan Mantlo , Eva Martin De La Nava , Ana Mateo Herranz , Daniel Mayhugh , Xiaodong Wang
发明人: Guoqing Cao , Ana Escribano , Maria Fernandez , Todd Fields , Douglas Gernert , Christopher Cioffi , Robert Herr , Nathan Mantlo , Eva Martin De La Nava , Ana Mateo Herranz , Daniel Mayhugh , Xiaodong Wang
IPC分类号: A61K31/55 , A61P9/10 , C07D223/14 , C07D223/16
CPC分类号: C07D223/16 , C07D223/14 , C07D223/32 , C07D225/06 , C07D403/04 , C07D403/12 , C07D405/06 , C07D405/12 , C07D413/04 , C07D491/04
摘要: Compounds of formula I wherein n, m, p, q, y, R1 R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.
摘要翻译: 其中n,m,p,q,y,R 1,R 2,R 3,R 4, R 5,R 5和R 6如本文所定义,并且它们的药物组合物和使用方法被公开用于治疗动脉粥样硬化及其后遗症。
-
公开(公告)号:US20060217433A1
公开(公告)日:2006-09-28
申请号:US10542579
申请日:2004-02-10
申请人: Scott Conner , Lynn Gosset , Jonathan Green , Winton Jones , Nathan Mantlo , Donald Matthews , Daniel Mayhugh , Daryl Smith , Jennifer Vance , Xiaodong Wang , Alan Warshawsky , Leonard Winneroski , Yanping Xu , Guoxin Zhu
发明人: Scott Conner , Lynn Gosset , Jonathan Green , Winton Jones , Nathan Mantlo , Donald Matthews , Daniel Mayhugh , Daryl Smith , Jennifer Vance , Xiaodong Wang , Alan Warshawsky , Leonard Winneroski , Yanping Xu , Guoxin Zhu
IPC分类号: A61K31/404 , A61K31/381 , A61K31/343 , A61K31/195 , C07D333/64
CPC分类号: C07D207/08 , A61K31/00 , A61K45/06 , C07C311/13 , C07C311/17 , C07C311/19 , C07C311/29 , C07C317/14 , C07C323/49 , C07C323/52 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D209/08 , C07D209/48 , C07D213/64 , C07D213/71 , C07D213/74 , C07D215/36 , C07D231/12 , C07D231/18 , C07D263/32 , C07D271/12 , C07D277/36 , C07D307/79 , C07D307/82 , C07D319/18 , C07D333/34 , C07D333/62 , C07D409/04 , C07D409/12 , C07D413/04 , A61K2300/00
摘要: The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.
摘要翻译: 本发明涉及式(I)化合物及其药学上可接受的盐,溶剂合物,水合物或立体异构体,其可用于治疗或预防由过氧化物酶体增殖物激活受体(PPAR)介导的病症,例如综合征X型 II型糖尿病,高血糖症,高脂血症,肥胖症,凝血病,高血压,动脉硬化以及与X综合症和心血管疾病有关的其他疾病。
-
-
-
-
-
-
-